Genmab A (GMAB) Interest Expenses (2019 - 2026)
Genmab A (GMAB) posted Interest Expenses of -$150.0 million for Q1 2026, up 11.76% on a QoQ basis from -$170.0 million in Q3 2025, and down 233.33% year-over-year from $112.5 million in Q1 2025.
Genmab A (GMAB) Interest Expenses (2019 - 2026) Analysis & Trends
Genmab A's Interest Expenses history runs 6 years deep, the most recent figure standing at -$150.0 million for Q1 2026.
- Quarterly Interest Expenses fell 233.33% year-over-year to -$150.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$454.0 million (down 44.13% YoY) and the FY2025 annual result came in at $269.0 million, down 7.56% from the prior year.
- Interest Expenses was -$150.0 million for Q1 2026 at Genmab A, up from -$170.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at -$9.0 million in Q4 2024 and bottomed at -$181.0 million in Q3 2024.
- A 4-year average of -$90.9 million and a median of -$80.0 million in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses jumped 35.71% — and 2026, when it plunged 233.33%.
- Genmab A's Interest Expenses stood at -$14.0 million in 2023, then soared by 35.71% to -$9.0 million in 2024, then tumbled by 1788.89% to -$170.0 million in 2025, then rose by 11.76% to -$150.0 million in 2026.
- Business Quant data shows GMAB's Interest Expenses at -$150.0 million in Q1 2026, -$170.0 million in Q3 2025, and -$134.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | -150.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -150.00 Mn |
| Mar 31, 2026 | -150.00 Mn |
| Sep 30, 2025 | -170.00 Mn |
| Sep 30, 2025 | -170.00 Mn |
| Jun 30, 2025 | -134.00 Mn |
| Jun 30, 2025 | -134.00 Mn |
| Mar 31, 2025 | -45.00 Mn |
| Mar 31, 2025 | -45.00 Mn |
| Dec 31, 2024 | -9.00 Mn |
| Dec 31, 2024 | -9.00 Mn |
| Sep 30, 2024 | -181.00 Mn |
| Sep 30, 2024 | -181.00 Mn |
| Jun 30, 2024 | -80.00 Mn |
| Jun 30, 2024 | -80.00 Mn |
| Mar 31, 2024 | -35.00 Mn |
| Mar 31, 2024 | -35.00 Mn |
| Dec 31, 2023 | -14.00 Mn |
| Dec 31, 2023 | -14.00 Mn |
| Sep 30, 2020 | -720.00 |
| Sep 30, 2020 | -720.00 |